CN105250269A - Application of Nagelamides X in preparation of drug for treating myocardial ischemia - Google Patents
Application of Nagelamides X in preparation of drug for treating myocardial ischemia Download PDFInfo
- Publication number
- CN105250269A CN105250269A CN201510749545.7A CN201510749545A CN105250269A CN 105250269 A CN105250269 A CN 105250269A CN 201510749545 A CN201510749545 A CN 201510749545A CN 105250269 A CN105250269 A CN 105250269A
- Authority
- CN
- China
- Prior art keywords
- myocardial ischemia
- nagelamides
- preparation
- drug
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides an application of Nagelamides X in preparation of a drug for treating or preventing myocardial ischemia/reperfusion. The application of Nagelamides X in preparation of the drug for treating myocardial ischemia is firstly disclosed; and the Nagelamides X has unexpected high inhibiting activity for myocardial ischemia because of a brand new skeleton type, is not possibly enlightened by other compounds, has prominent substantive features and obviously has a remarkable progress when used for treating myocardial ischemia.
Description
Technical field
The present invention relates to the novelty teabag of compound N agelamidesX, particularly relate to the application of NagelamidesX in preparation treatment myocardial ischemia drug.
Background technology
The present inventor is found by a large amount of experiments, and NagelamidesX has the/pharmacological action of reperfusion injury that resists myocardial ischemia, and has the medical usage of prevention or treatment myocardial ischemia disease.
The compound N agelamidesX that the present invention relates to is one and delivers (NaonobuTanaka in 2013, etal., NagelamidesXZ, DimericBromopyrroleAlkaloidsfromaMarineSpongeAgelassp.Or ganicLetters13 (15), 3262 – 3265.) noval chemical compound, this compound has brand-new framework types, current purposes only relates to antibacterial (NaonobuTanaka, etal., NagelamidesXZ, DimericBromopyrroleAlkaloidsfromaMarineSpongeAgelassp.Or ganicLetters13 (15), 3262 – 3265.), the purposes of the NagelamidesX that the present invention relates in preparation treatment myocardial ischemia drug is belonged to first public, owing to belonging to brand-new structure type, and it is active unexpectedly strong for treatment myocardial ischemia, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control simultaneously for myocardial ischemia obviously has significant progress.
Summary of the invention
The invention provides the application in the medicine of NagelamidesX preparation treatment or prevention Ischemic/reperfusion.
The present inventor demonstrates by the experiment in detailed description of the invention the effect that NagelamidesX has treatment or prevention myocardial ischemia drug disease.
Described compound N agelamidesX structure is as shown in formula I:
The NagelamidesX that the present invention relates to belongs to first public preparing the purposes in medicaments for resisting myocardial ischemia, because framework types belongs to brand-new framework types, and its inhibit activities for myocardial ischemia is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possessing outstanding substantive distinguishing features, for resisting myocardial ischemia, obviously there is significant progress simultaneously.
Detailed description of the invention
The preparation method of compound N agelamidesX involved in the present invention is see document (NaonobuTanaka, etal., NagelamidesXZ, DimericBromopyrroleAlkaloidsfromaMarineSpongeAgelassp.Or ganicLetters13 (15), 3262 – 3265.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound N agelamidesX tablet involved in the present invention:
Get 20 g of compound NagelamidesX and add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound N agelamidesX capsule involved in the present invention:
Get 20 g of compound NagelamidesX add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example: NagelamidesX is on the impact of myocardial ischemia/reperfusion injury in rats
(1) experiment material: SD rat, male and female dual-purpose, body weight 190 ~ 210g.
(2) method and result
1) experimental technique
The acute myocardial ischemia experiment of pituitrin induction: rat is divided into 5 groups at random: positive controls, negative control group, administration group 3 groups, often organizes 8.Administration group gastric infusion, two matched groups give the distilled water gavage of consubstantiality accumulated amount every day, the continuous gavage 7d of each group.All after the 7th day gavage, 1.5 ~ 2.0h lumbar injection pentobarbital sodium 30mg/kg anaesthetizes, and adopts MS2302 multimedia biological signal collecting analytical system to continue record standard II lead electrocardiogram.The Electrocardiographic change of record 15min continuously after experimental group, positive controls sublingual vein injection of pituitrin 5IU/kg (complete in 5s, positive controls is 10min lumbar injection nitroglycerin 5mg/kg before injection of pituitrin) 10min.If there is one of following change in electrocardiogram: T ripple is low flat, two-way, and be inverted, ST section level moves down >=0.05mV, gives note 1 point.Finally analyze the total score of every rat, as reduced after medication score, prompting myocardial ischemia is improved.The impact of medicine on heart rate is represented with changes in heart rate percentage rate before and after injection of pituitrin.
Cardiac muscle ischemia resisting reperfusion injury experiment: rat is divided into 5 groups at random: positive controls, negative control group, administration group 3 groups, often organizes 8.Administration group gastric infusion, two matched groups give the distilled water gavage of consubstantiality accumulated amount every day, each continuous gavage 7d.Record standard II lead electrocardiogram after rats by intraperitoneal injection pentobarbital sodium 30mg/kg anaesthetizes.Tracheal intubation, connect artificial respirator (1.0mlg-1min-1), thoracic cavity is opened at 4th ~ 5 intercostals, expose heart, at pulmonary conus left border, left auricle lower edge 1mm place is with 320 silk thread ligation ramus descendens anterior arteriae coronariae sinistraes (positive controls is 3min sublingual vein injection Propranolol 1.0mg/kg before following coronary artery occlusion).After ligation 30min, cut off ligature, fill with 30min again.Quick taking-up heart, rinses well with 0.9% sodium chloride.Myocardium sheet is placed in the TTC solution of 1%, in 37 DEG C of hatching 5min.Rinse with water immediately after dyeing and remove dyestuff unnecessary on myocardium sheet.Cut off the non-infarcted region cardiac muscle that each myocardium sheet is colored, undyed infarcted myocardium and ischemic myocardium are weighed.
Hemodynamics is tested: rat is divided into 5 groups at random: positive controls, negative control group, administration group 3 groups, often organizes 8.Administration group gastric infusion, two matched groups give the distilled water gavage of consubstantiality accumulated amount every day, the continuous gavage 5d of each group.Within 6th day, lumbar injection urethane 10mg/kg anaesthetizes.Record standard II lead electrocardiogram.Longitudinally cut right skin of neck, be separated right common carotid artery, insert the left ventricular catheter being full of heparin 0.9% sodium chloride, conduit is slowly inserted left ventricular cavity.Cut left lower extremity inside skin, be separated femoral artery, insert ductus arteriosus.Cut-in pressure transducer, transports to multimedia bio signal monitor signal and observes.After balance 30min, each hemodynamic index before record administration.All data all represent with x ± s, and experimental group and the matched group data analysis sided t of two sample averages are checked.
2) result
Ischemia/reperfusion injury experimental result shows, under administration group, positive controls, negative control group myocardial infarction and ligature, myocardial Mass Measured percentage ratio is respectively in table 1.
Table 1NagelamidesX is on the impact of scheming weight ratio under myocardial infarction and ligature
Compare with negative control group, * * p<0.01, * p<0.05
NagelamidesX on the impact of the acute myocardial ischemia that pituitrin causes in table 2.
Table 2NagelamidesX is on the impact of the acute myocardial ischemia that pituitrin causes
Compare with negative control group, * * p<0.01, * p<0.05
Conclusion: NagelamidesX can reduce the generation of myocardial infarction, and NagelamidesX obviously can change the change of electrocardio degree, does not change heart rate.More than experiment can illustrate, NagelamidesX can treat myocardial ischemia/perfusion.
Claims (1)
- The application of 1.NagelamidesX in treatment myocardial ischemia drug, described compound N agelamidesX structure is as shown in formula I:Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510749545.7A CN105250269A (en) | 2015-11-05 | 2015-11-05 | Application of Nagelamides X in preparation of drug for treating myocardial ischemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510749545.7A CN105250269A (en) | 2015-11-05 | 2015-11-05 | Application of Nagelamides X in preparation of drug for treating myocardial ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105250269A true CN105250269A (en) | 2016-01-20 |
Family
ID=55090408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510749545.7A Withdrawn CN105250269A (en) | 2015-11-05 | 2015-11-05 | Application of Nagelamides X in preparation of drug for treating myocardial ischemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105250269A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103479609A (en) * | 2013-10-11 | 2014-01-01 | 淄博齐鼎立专利信息咨询有限公司 | Application of Scopariusins in preparation of myocardial ischemia treatment medicines |
| CN103768051A (en) * | 2012-10-25 | 2014-05-07 | 南京大学 | Application of Eryngiolide A in drug for treating myocardial ischemia |
-
2015
- 2015-11-05 CN CN201510749545.7A patent/CN105250269A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768051A (en) * | 2012-10-25 | 2014-05-07 | 南京大学 | Application of Eryngiolide A in drug for treating myocardial ischemia |
| CN103479609A (en) * | 2013-10-11 | 2014-01-01 | 淄博齐鼎立专利信息咨询有限公司 | Application of Scopariusins in preparation of myocardial ischemia treatment medicines |
Non-Patent Citations (1)
| Title |
|---|
| NAONOBU TANAKA，等: "Nagelamides X-Z, Dimeric Bromopyrrole Alkaloids from a Marine Sponge Agelas sp.", 《ORGANIC LETTER》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103638012B (en) | Application of Myrtucommuacetalone in medicine for treatment of myocardial ischemia | |
| CN103768051B (en) | The application of Eryngiolide A in preparation treatment myocardial ischemia drug | |
| CN103520170B (en) | Kadcoccitones A application in preparation treatment myocardial ischemia drug | |
| CN105412073A (en) | Application of Spirooliganone B in preparation of myocardial ischemia treatment drug | |
| CN103393703B (en) | The application of Houttuynoid B in preparation treatment myocardial ischemia drug | |
| CN103356681B (en) | The application of Houttuynoid A in preparation treatment myocardial ischemia drug | |
| CN103381182B (en) | The application of Houttuynoid C in preparation treatment myocardial ischemia drug | |
| CN103356647B (en) | The application of Chukrasone A in preparation treatment myocardial ischemia drug | |
| CN103751182B (en) | The application of a kind of compound in treatment myocardial ischemia drug | |
| CN103356595B (en) | The application of Chukrasone B in preparation treatment myocardial ischemia drug | |
| CN105250269A (en) | Application of Nagelamides X in preparation of drug for treating myocardial ischemia | |
| CN105380940A (en) | Use of Rhodomicranols B in preparation of drug for treating myocardial ischemia | |
| CN106344579A (en) | Application of Fistulains A in drugs for myocardial ischemia treatment | |
| CN105412068A (en) | Application of Rearranged abietane diterpenoid in preparation of drugs for treating myocardial ischemia | |
| CN103479609A (en) | Application of Scopariusins in preparation of myocardial ischemia treatment medicines | |
| CN102988351A (en) | Application of Aphanamixoid A for preparing medicine for treating myocardial ischemia | |
| CN105168207A (en) | Medicine for treating myocardial ischemia and application thereof | |
| CN102861035B (en) | Application of Gypensapogenin B in medicine for treating myocardial ischemia | |
| CN103263424A (en) | Application of Myriberine A in preparation of medicine for treating myocardial ischemia | |
| CN103340886A (en) | Application of Polyflavanostilbene A in preparation of medicine for treating myocardial ischemia | |
| CN106309437A (en) | Application of Ternatusine A in preparation of medicaments for treating myocardial ischemia | |
| CN103610678B (en) | The application of Trigolutesins A in treatment myocardial ischemia drug | |
| CN103356546A (en) | Application of Sarcaboside B in medicine used for treating myocardial ischemia | |
| CN103463008A (en) | Application of racemosins A in preparation of medicine treating myocardial ischemia | |
| CN103356676A (en) | Application of Houttuynoid E in medicine for treating myocardial ischemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160120 |
|
| WW01 | Invention patent application withdrawn after publication |